We are live on
!
Find out more
PCM
Portolan Capital Management Portfolio holdings
AUM
$2.67B
1-Year Est. Return
169.09%
This Fund
S&P 500
This Quarter
Est. Return
+3.72%
1 Year Est. Return
+169.09%
3 Year Est. Return
+737.83%
5 Year Est. Return
+1,497.12%
10 Year Est. Return
+21,256.61%
AUM
$1.21B
AUM Growth
-$98.5M
(-7.5%)
Cap. Flow
-$79M
Cap. Flow
% of AUM
-6.5%
Top 10 Holdings %
Top 10 Hldgs %
27.39%
Holding
137
New
21
Increased
36
Reduced
59
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Quanterix
QTRX
|
+$12.6M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
+$11.6M |
| 3 |
TTM Technologies
TTMI
|
+$11.5M |
| 4 |
Orion Group Holdings
ORN
|
+$11.2M |
| 5 |
Maravai LifeSciences
MRVI
|
+$10.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bio-Rad Laboratories Class A
BIO
|
+$19.2M |
| 2 |
WKME
WalkMe Ltd. Ordinary Shares
WKME
|
+$19.1M |
| 3 |
Sweetgreen
SG
|
+$15.8M |
| 4 |
United Therapeutics
UTHR
|
+$14.8M |
| 5 |
RCM
R1 RCM Inc. Common Stock
RCM
|
+$14.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.79% |
| 2 | Healthcare | 21.3% |
| 3 | Industrials | 12.49% |
| 4 | Consumer Discretionary | 8.15% |
| 5 | Communication Services | 6.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Lantronix
LTRX
$246M
| – | – |
-578,180
| Closed | -$2.06M |
|
127
Pagaya Technologies
PGY
$1.84B
| – | – |
-149,584
| Closed | -$1.51M |
|
128
Playboy Inc
PLBY
$141M
| – | – |
-289,354
| Closed | -$304K |
|
129
Porch Group
PRCH
$1.9B
| – | – |
-631,459
| Closed | -$2.72M |
|
130
Richardson Electronics
RELL
$262M
| – | – |
-11,950
| Closed | -$110K |
|
131
Royalty Pharma
RPRX
$27B
| – | – |
-288,378
| Closed | -$8.76M |
|
132
TH International
THCH
$43.2M
| – | – |
-155,248
| Closed | -$893K |
|
133
TechTarget
TTGT
$293M
| – | – |
-162,883
| Closed | -$5.39M |
|
|
UCTT
134
Ultra Clean Holdings
UCTT
$3.42B
| – | – |
-99,992
| Closed | -$4.59M |
|
|
RCM
135
DELISTED
R1 RCM Inc. Common Stock
RCM
| – | – |
-1,097,612
| Closed | -$14.1M |
|
|
NVEI
136
DELISTED
Nuvei Corporation Subordinate Voting Shares
NVEI
| – | – |
-154,989
| Closed | -$4.9M |
|
|
OSG
137
DELISTED
Overseas Shipholding Group Inc.
OSG
| – | – |
-771,227
| Closed | -$4.94M |
|
Similar funds
IAS
ORIO
BWFA
RIL
MMC
TCOV
UPS
Portolan Capital Management's Q2 2024 Portfolio in Review
As of Q2 2024, Portolan Capital Management held 137 positions worth $1.21B, down 7.5% from $1.31B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Portolan Capital Management withdrew a net $79M in Q2 2024, closing 20 positions and reducing 59 holdings. Its most notable exit was R1 RCM Inc. Common Stock, an estimated $14.1M position sold in full.
By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 35% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Portolan Capital Management opened a new position in Phathom Pharmaceuticals worth $11.6M.
- Portolan Capital Management's largest Q2 2024 buy was Phathom Pharmaceuticals: 1,130,089 shares worth $11.6M.
- Portolan Capital Management added most to Quanterix in Q2 2024, an estimated $12.6M increase.
- Portolan Capital Management's biggest Q2 2024 reduction was Bio-Rad Laboratories Class A, cutting an estimated $19.2M.
- Portolan Capital Management fully exited R1 RCM Inc. Common Stock in Q2 2024, selling an estimated $14.1M.
- Portolan Capital Management's ten largest holdings make up 27% of its $1.21B portfolio in Q2 2024.
- Portolan Capital Management opened 21 new positions and closed 20 in Q2 2024.
- Portolan Capital Management's portfolio value fell 7.5% quarter-over-quarter to $1.21B.
Based on Portolan Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.